pocketful logo light
pocketful logo light
Glaxosmithkline Pharmaceuticals Ltd logo

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO BSE: 500660

₹2346.80

(1.78%)

Mon, 25 May 2026, 08:52 pm

Glaxosmithkline Pharmaceuticals Share Price Live Chart

1 Day

(1.78%)

No Result Found

Summary

  • Market Cap

    39129.41

  • Net Profit

    927.58

  • P/B

    24.98

  • Sector P/E

    34.11

  • P/E

    52.54

  • EV/EBITDA

    35.66

  • Debt/Equity (Industry)

    0.08

  • Interest Cover (Industry)

    42.77

  • ROCE (Industry)

    23.88

  • RONW (Industry)

    19.04

  • ROE

    49.75

  • ROCE

    59.29

  • Debt/Equity

    0.01

  • EPS (TTM)

    60.26

  • Dividend Yield

    2.47

  • Book Value

    133.85

  • Interest Cover

    962.74

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends after 3 years are expected to be covered by earnings (1.5x coverage).
  • GlaxoSmithKline Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • GlaxoSmithKline Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • GlaxoSmithKline Pharmaceuticals's earnings growth is expected to exceed the India market average.
thumbs up icon

Cons

  • Dividends paid are not well covered by earnings (0.3x coverage).
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • GlaxoSmithKline Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for GlaxoSmithKline Pharmaceuticals is expected to increase but not above the 50% threshold in 2 years time.
  • GlaxoSmithKline Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters7575757575
FII4.624.644.794.884.52
DII7.687.707.757.707.79
Public12.7012.6612.4512.4112.69
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

36.23

MACD

-22.65

50 DMA

2393.01

200 DMA

2555.60

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2912.072644.072490.232376.072222.232108.071840.07
Fibonacci2644.072541.692478.442376.072273.692210.442108.07
Camarilla2410.102385.532360.972376.072311.832287.272262.70

Pivots Level: Classic

R3

+536

2912.07

R2

+268

2644.07

R1

+114.17

2490.23

2376.07
2376.07
Pivot Point
LTP: 2300.10

S1

-153.83

2222.23

S2

-268

2108.07

S3

-536

1840.07

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2359.69

  • 20-EMA

    2382.72

  • 30-EMA

    2393.06

  • 50-EMA

    2409.11

  • 100-EMA

    2454.43

  • 200-EMA

    2530.50

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 May 2026board-meetingsAccounts, Quarterly Results, Dividend
13 May 2026dividend₹57.00 Dividend /Share29 May 2026
13 May 2026agm
09 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
13 May 2025agm
13 May 2025dividend₹42.00 Dividend /Share30 May 2025
30 Apr 2025dividendFinal Dividend - Rs. - 4230 May 2025
29 Oct 2024dividend₹12.00 Dividend /Share07 Nov 2024
07 Oct 2024dividendInterim Dividend - Rs. - 1207 Nov 2024

Read More

Peer Comparison

Glaxosmithkline Pharmaceuticals Ltd logo

Glaxosmithkline Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

Glaxosmithkline Pharmaceuticals Ltd About

GlaxoSmithKline Pharmaceuticals is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

Industry

Pharmaceuticals - Multinational

Founded

1924

Headquarters

CEO

Renu S Karnad

Employees

Contact

Website icon

Website

http://www.gsk-india.com

Email icon

Email

askus@gsk.com; ajay.a.nadkarni@gsk.com

Phone icon

Phone

91-022-24959595

Location icon

Location

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Read More

Glaxosmithkline Pharmaceuticals Ltd Company History

YearHistory
2019
  • Won Brand of the Year award in acute category at 6th AWACS Awards.
  • Won Best Sales and Operations Planning Practice in Pharma award.
  • Recognised as Best Workplaces for Women by Great Places to Work India.
2020
  • Recognised as one of 100 Best Companies for Women in India by Working Mother and AVTAR.
  • Conferred Fair Business Practices award (2019-20) by Council for Fair Business Practices.
  • Recognised as Silver employer under India Workplace Equality Index.
2021
  • Recognised as one of India's Best Workplaces in Health & Wellness by Great Place to Work.
  • Conferred CNBC TV18 India Risk Management Award in Pharma sector.
2022
  • Launched once-daily single inhaler-triple therapy for COPD patients.
  • Teamed up with MS Dhoni for 6-in-1 vaccination awareness campaign.
2024
  • Reported strong double-digit growth and improved profitability for the quarter.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell806151378.6517 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy806151378.6517 Oct 2022
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy118411378.6517 Oct 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell118411378.6517 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy777341393.4511 Oct 2022
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy114171393.4511 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell777341393.4511 Oct 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell114171393.4511 Oct 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell113731424.403 Oct 2022
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy113731424.403 Oct 2022

Read More

Glaxosmithkline Pharmaceuticals Ltd News

GSK Pharma Q4 FY26 Earnings Call: Key Highlights

GSK Pharma held its Q4 FY26 earnings call on May 13, 2026. Full-year revenues up 2%, EBITDA grew 11%, PAT up 10%, first-ever PAT ex-exceptionals crossed INR1,000 crores.

18 May 2026

companies

GSK Pharma Completes Investor Meet on May 13, 2026

GlaxoSmithKline Pharmaceuticals completed its digital analyst and institutional investor meeting on May 13, 2026, with the recording uploaded per SEBI Regulation 30.

13 May 2026

companies

GSK Pharma FY26 Net Profit Rises to Rs. 103598 Lakhs

GlaxoSmithKline Pharmaceuticals posts consolidated net profit of Rs. 103598 lakhs for FY26, up from Rs. 92758 lakhs in FY25. Board recommends final dividend of Rs. 57 per share.

13 May 2026

companies

GSK Pharma Schedules Investor Meet on May 13, 2026

GlaxoSmithKline Pharmaceuticals has announced a digital group analyst and institutional investor meeting on May 13, 2026, under SEBI Listing Regulations.

08 May 2026

companies

GSK Pharma Schedules Investor Meet on May 13, 2026

GlaxoSmithKline Pharmaceuticals has announced a digital group analyst and institutional investor meeting on May 13, 2026, under SEBI Listing Regulations.

07 May 2026

companies

Read More